Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.syngeneintl.com | |
Market Cap | 28,601.36 Cr. | |
Enterprise Value(EV) | 28,203.16 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 12.40 | Trailing Twelve Months Ending 2023-09 |
Price-Earning Ratio (PE) | 57.40 | Trailing Twelve Months Ending 2023-09 |
Industry PE | 38.33 | Trailing Twelve Months Ending 2023-09 |
Book Value / Share | 96.79 | Trailing Twelve Months Ending 2023-09 |
Price to Book Value | 7.35 | Calculated using Price: 711.45 |
Dividend Yield | 0.18 | Period Ending 2023-03 |
No. of Shares Subscribed | 40.20 Cr. | 402,015,000 Shares |
FaceValue | 10 | |
About Syngene International Ltd. | ||
The company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Services offered by the company are Discovery Chemistry, Discovery Biology, Safety Assessment, Large Molecule Development, Chemical Development, Formulation Development, Stability Studies, Polymer Research, Integrated Discovery & Development, Clinical Development Services, Bioinformatics, Antibody Drug Conjugates, Oligonucleotide Synthesis. |
1 Day |
|
-1.58% |
1 Week |
|
-4.69% |
1 Month |
|
-1.67% |
3 Month |
|
-15.24% |
6 Month |
|
-1.66% |
1 Year |
|
+21.24% |
2 Year |
|
+19.70% |
5 Year |
|
+164.07% |
10 Year |
|
6 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 18.05 | 18.26 | 20.21 | 16.59 | 13.29 | 13.73 | |
Return on Capital Employed (%) | 15.76 | 16.98 | 19.60 | 15.40 | 13.24 | 15.43 | |
Return on Assets (%) | 9.80 | 9.86 | 10.77 | 9.17 | 7.69 | 8.25 |
Particulars | 7 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 1,720 | 1,968 | 2,176 | 2,821 | 3,298 | 3,618 | 3,891 | |
Non Curr. Liab. | 613 | 515 | 325 | 840 | 972 | 955 | 681 | |
Curr. Liab. | 784 | 1,129 | 1,539 | 1,133 | 1,229 | 1,188 | 1,226 | |
Minority Int. | ||||||||
Equity & Liab. | 3,117 | 3,612 | 4,040 | 4,794 | 5,498 | 5,761 | 5,798 | |
Non Curr. Assets | 1,396 | 1,848 | 2,428 | 2,987 | 3,292 | 3,336 | 3,423 | |
Curr. Assets | 1,720 | 1,764 | 1,613 | 1,807 | 2,206 | 2,425 | 2,375 | |
Misc. Exp. not W/O | ||||||||
Total Assets | 3,117 | 3,612 | 4,040 | 4,794 | 5,498 | 5,761 | 5,798 |
Particulars | 7 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
Net Sales | 1,423 | 1,826 | 2,012 | 2,184 | 2,604 | 3,193 | 3,499 | |
Other Income | 136 | 76 | 96 | 83 | 108 | 73 | 85 | |
Total Income | 1,559 | 1,902 | 2,108 | 2,268 | 2,713 | 3,266 | 3,584 | |
Total Expenditure | -1,033 | -1,290 | -1,409 | -1,531 | -1,864 | -2,260 | -2,487 | |
PBIDT | 527 | 612 | 700 | 736 | 849 | 1,005 | 1,096 | |
Interest | -23 | -32 | -35 | -28 | -24 | -45 | -48 | |
Depreciation | -131 | -164 | -219 | -275 | -310 | -367 | -397 | |
Taxation | -67 | -84 | -105 | -64 | -89 | -129 | -146 | |
Exceptional Items | 71 | 35 | -31 | -7 | ||||
PAT | 305 | 332 | 412 | 405 | 396 | 464 | 498 | |
Minority Interest | ||||||||
Share Associate | ||||||||
Other Related Items | ||||||||
Consolidated Net Profit | 305 | 332 | 412 | 405 | 396 | 464 | 498 | |
Adjusted EPS | 8 | 8 | 10 | 10 | 10 | 12 | 12 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 446 | 630 | 677 | 701 | 581 | 824 | |
Cash Fr. Inv. | -349 | -647 | -428 | -628 | -612 | -656 | |
Cash Fr. Finan. | -79 | -72 | -226 | 58 | -31 | -343 | |
Net Change | 18 | -89 | 23 | 131 | -62 | -175 | |
Cash & Cash Eqvt | 253 | 165 | 193 | 323 | 262 | 90 |
Mon, 11 Dec 2023
Analyst/Institutional Investor Meeting Enclosed herewith are the details of the meeting to be held with the Analyst/Institutional Investor. |
Thu, 07 Dec 2023
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Disclosure pursuant to Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 |
Wed, 06 Dec 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find below the details of the meeting to be held with Analyst/Institutional investor. |
Mon, 11 Dec 2023 |
|
|
|
|
|